MEI Pharma (MEIP) Stock Forecast, Price Target & Predictions
MEIP Stock Forecast
MEI Pharma stock forecast is as follows: a rating consensus of 'Hold', based on 3 wall street analysts offering a 1-year stock forecast.
MEIP Analyst Ratings
According to 3 Wall Street analysts, MEI Pharma's rating consensus is 'Hold'. The analyst rating breakdown for MEIP stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 3 'Hold' (100.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 23, 2024 | Laidlaw | - | Hold | Downgrade |
| Jul 22, 2024 | Brookline Capital | Buy | Hold | Downgrade |
| Feb 08, 2023 | Jefferies | - | Underperform | Downgrade |
| Dec 06, 2022 | BTIG | - | Neutral | Downgrade |
| Apr 12, 2022 | Brookline Capital | Buy | Buy | Hold |
MEI Pharma's last stock rating was published by Laidlaw on Jul 23, 2024. The company Downgrade its MEIP rating from "null" to "Hold".
MEI Pharma Financial Forecast
MEI Pharma Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 08 | Mar 07 | Mar 06 | Mar 05 | Mar 04 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | $5.89M | $32.73M | $8.73M | $11.41M | $9.69M | $18.22M | $13.39M | $10.12M | $2.42M | $9.17M | $3.83M | $25.50M | $1.24M | $1.01M | $1.16M | $1.13M | $1.25M | $433.00K | $4.50M | - | - | - | - | - |
| Avg Forecast | - | - | $50.00K | $37.50K | $100.00K | $620.67K | $346.75K | $4.42M | $4.42M | $4.78M | $3.44M | $5.26M | $10.56M | $4.17M | $5.41M | $2.92M | $3.67M | $45.07M | $1.58M | $1.58M | $1.33M | $715.86K | $690.71K | $645.00K | $9.02M | $440.40K | $456.00K | $83.33K | $93.33K | $53.33K |
| High Forecast | - | - | $50.00K | $37.75K | $100.00K | $620.67K | $346.75K | $4.42M | $4.42M | $4.78M | $3.44M | $5.26M | $10.56M | $4.17M | $5.41M | $2.92M | $3.67M | $45.07M | $1.58M | $1.58M | $1.33M | $715.86K | $690.71K | $774.00K | $10.82M | $528.48K | $547.20K | $100.00K | $112.00K | $64.00K |
| Low Forecast | - | - | $50.00K | $37.25K | $100.00K | $620.67K | $346.75K | $4.42M | $4.42M | $4.78M | $3.44M | $5.26M | $10.56M | $4.17M | $5.41M | $2.92M | $3.67M | $45.07M | $1.58M | $1.58M | $1.33M | $715.86K | $690.71K | $516.00K | $7.22M | $352.32K | $364.80K | $66.67K | $74.67K | $42.66K |
| # Analysts | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 16 | 12 | 14 | 9 | 16 | 11 |
| Surprise % | - | - | - | - | - | - | 17.00% | 7.41% | 1.98% | 2.39% | 2.82% | 3.46% | 1.27% | 2.43% | 0.45% | 3.14% | 1.05% | 0.57% | 0.79% | 0.64% | 0.87% | 1.58% | 1.81% | 0.67% | 0.50% | - | - | - | - | - |
MEI Pharma's average Quarter revenue forecast for Jun 23 based on 1 analysts is $620.67K, with a low forecast of $620.67K, and a high forecast of $620.67K. MEIP's average Quarter revenue forecast represents a -89.47% decrease compared to the company's last Quarter revenue of $5.89M (Mar 23).
MEI Pharma EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 08 | Mar 07 | Mar 06 | Mar 05 | Mar 04 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 16 | 12 | 14 | 9 | 16 | 11 |
| EBITDA | - | - | - | - | $-11.93M | - | $-16.29M | $8.53M | $-19.24M | $-16.04M | $-34.33M | $-5.69M | $-11.80M | $-5.65M | $-31.24M | $-11.38M | $-2.02M | $-18.46M | $-4.30M | $-20.19M | $-2.96M | $3.08M | $-17.33M | $-5.93M | $-589.00K | - | - | - | - | - |
| Avg Forecast | - | - | $-22.70K | $-10.95M | $-45.39K | $-281.74K | $-11.71M | $-7.00M | $-2.01M | $-2.17M | $-12.52M | $-2.39M | $-4.80M | $-1.89M | $-28.82M | $-1.32M | $-1.67M | $-20.46M | $-6.63M | $-715.84K | $-603.34K | $-324.95K | $-11.21M | $-7.91M | $-795.15K | $-3.89M | $-2.52M | $-2.60M | $-2.17M | $-847.55K |
| High Forecast | - | - | $-22.70K | $-8.76M | $-45.39K | $-281.74K | $-9.37M | $-5.60M | $-2.01M | $-2.17M | $-10.02M | $-2.39M | $-4.80M | $-1.89M | $-23.06M | $-1.32M | $-1.67M | $-20.46M | $-5.31M | $-715.84K | $-603.34K | $-324.95K | $-8.97M | $-6.33M | $-636.12K | $-3.11M | $-2.01M | $-2.08M | $-1.74M | $-678.04K |
| Low Forecast | - | - | $-22.70K | $-13.14M | $-45.39K | $-281.74K | $-14.05M | $-8.40M | $-2.01M | $-2.17M | $-15.03M | $-2.39M | $-4.80M | $-1.89M | $-34.59M | $-1.32M | $-1.67M | $-20.46M | $-7.96M | $-715.84K | $-603.34K | $-324.95K | $-13.46M | $-9.50M | $-954.18K | $-4.66M | $-3.02M | $-3.12M | $-2.61M | $-1.02M |
| Surprise % | - | - | - | - | 262.82% | - | 1.39% | -1.22% | 9.59% | 7.40% | 2.74% | 2.38% | 2.46% | 2.98% | 1.08% | 8.60% | 1.21% | 0.90% | 0.65% | 28.20% | 4.91% | -9.48% | 1.55% | 0.75% | 0.74% | - | - | - | - | - |
1 analysts predict MEIP's average Quarter EBITDA for Mar 23 to be $-11.71M, with a high of $-9.37M and a low of $-14.05M. This is -237.23% lower than MEI Pharma's previous annual EBITDA (Dec 22) of $8.53M.
MEI Pharma Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 08 | Mar 07 | Mar 06 | Mar 05 | Mar 04 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 16 | 12 | 14 | 9 | 16 | 11 |
| Net Income | - | - | - | - | $-11.06M | - | $-14.48M | $10.25M | $-17.10M | $-16.27M | $16.97M | $-5.77M | $-11.88M | $-5.72M | $-31.31M | $-11.45M | $-2.09M | $-18.48M | $-4.33M | $-20.22M | $-2.99M | $3.05M | $-17.36M | $-5.95M | $-602.00K | - | - | - | - | - |
| Avg Forecast | $-14.65M | $-11.32M | $-9.37M | $-11.06M | $-9.41M | $-18.63M | $-11.83M | $-7.09M | $-22.31M | $-25.64M | $-12.65M | $-25.16M | $-17.51M | $-22.45M | $-28.89M | $-17.54M | $-10.92M | $28.64M | $-6.68M | $-21.84M | $-21.98M | $-25.88M | $-11.23M | $-7.93M | $-812.70K | $-3.89M | $-2.52M | $-2.60M | $-2.17M | $-847.55K |
| High Forecast | $-14.65M | $-11.32M | $-9.37M | $-8.85M | $-8.57M | $-18.63M | $-9.46M | $-5.67M | $-22.31M | $-25.64M | $-10.12M | $-25.16M | $-17.51M | $-22.45M | $-23.11M | $-17.54M | $-10.92M | $28.64M | $-5.34M | $-21.84M | $-21.98M | $-25.88M | $-8.98M | $-6.34M | $-650.16K | $-3.11M | $-2.02M | $-2.08M | $-1.74M | $-678.04K |
| Low Forecast | $-14.65M | $-11.32M | $-9.37M | $-13.27M | $-10.25M | $-18.63M | $-14.19M | $-8.51M | $-22.31M | $-25.64M | $-15.18M | $-25.16M | $-17.51M | $-22.45M | $-34.67M | $-17.54M | $-10.92M | $28.64M | $-8.01M | $-21.84M | $-21.98M | $-25.88M | $-13.48M | $-9.52M | $-975.24K | $-4.66M | $-3.02M | $-3.12M | $-2.61M | $-1.02M |
| Surprise % | - | - | - | - | 1.18% | - | 1.22% | -1.45% | 0.77% | 0.63% | -1.34% | 0.23% | 0.68% | 0.25% | 1.08% | 0.65% | 0.19% | -0.65% | 0.65% | 0.93% | 0.14% | -0.12% | 1.55% | 0.75% | 0.74% | - | - | - | - | - |
MEI Pharma's average Quarter net income forecast for Mar 23 is $-11.83M, with a range of $-14.19M to $-9.46M. MEIP's average Quarter net income forecast represents a -215.37% decrease compared to the company's last Quarter net income of $10.25M (Dec 22).
MEI Pharma SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 08 | Mar 07 | Mar 06 | Mar 05 | Mar 04 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 16 | 12 | 14 | 9 | 16 | 11 |
| SG&A | - | - | - | - | $8.02M | - | $7.18M | $8.50M | $7.49M | $5.77M | $8.93M | $7.93M | $7.91M | $6.63M | $6.21M | $5.65M | $5.92M | $4.53M | $3.86M | $4.20M | $4.13M | $3.74M | $3.63M | $2.49M | $2.15M | - | - | - | - | - |
| Avg Forecast | - | - | $33.20K | $24.90K | $66.40K | $412.14K | $230.25K | $2.93M | $2.93M | $3.17M | $2.28M | $3.49M | $7.01M | $2.77M | $3.59M | $1.94M | $2.44M | $29.93M | $1.05M | $1.05M | $882.60K | $475.35K | $458.65K | $428.30K | $2.91M | $292.44K | $302.80K | $55.34K | $61.98K | $35.41K |
| High Forecast | - | - | $33.20K | $25.07K | $66.40K | $412.14K | $230.25K | $2.93M | $2.93M | $3.17M | $2.28M | $3.49M | $7.01M | $2.77M | $3.59M | $1.94M | $2.44M | $29.93M | $1.05M | $1.05M | $882.60K | $475.35K | $458.65K | $513.96K | $3.49M | $350.92K | $363.36K | $66.40K | $74.37K | $42.50K |
| Low Forecast | - | - | $33.20K | $24.73K | $66.40K | $412.14K | $230.25K | $2.93M | $2.93M | $3.17M | $2.28M | $3.49M | $7.01M | $2.77M | $3.59M | $1.94M | $2.44M | $29.93M | $1.05M | $1.05M | $882.60K | $475.35K | $458.65K | $342.64K | $2.32M | $233.95K | $242.24K | $44.27K | $49.58K | $28.33K |
| Surprise % | - | - | - | - | 120.75% | - | 31.19% | 2.90% | 2.55% | 1.82% | 3.91% | 2.27% | 1.13% | 2.40% | 1.73% | 2.92% | 2.43% | 0.15% | 3.69% | 4.01% | 4.68% | 7.88% | 7.92% | 5.80% | 0.74% | - | - | - | - | - |
MEI Pharma's average Quarter SG&A projection for Mar 24 is $24.90K, based on 1 Wall Street analysts, with a range of $24.73K to $25.07K. The forecast indicates a -99.69% fall compared to MEIP last annual SG&A of $8.02M (Dec 23).
MEI Pharma EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 08 | Mar 07 | Mar 06 | Mar 05 | Mar 04 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 16 | 12 | 14 | 9 | 16 | 11 |
| EPS | - | - | - | - | $-1.66 | - | $-2.17 | $0.08 | $-0.13 | $-0.13 | $0.13 | $-0.05 | $-0.11 | $-0.05 | $-0.28 | $-0.10 | $-0.02 | $-0.16 | $-0.04 | $-0.26 | $-0.04 | $0.04 | $-0.24 | $-0.16 | $-0.02 | - | - | - | - | - |
| Avg Forecast | $-2.20 | $-1.70 | $-1.41 | $-1.49 | $-1.41 | $-2.80 | $-2.90 | $-3.03 | $-3.35 | $-3.85 | $-3.67 | $-3.78 | $-2.63 | $-3.37 | $-3.12 | $-2.63 | $-1.64 | $4.30 | $-2.60 | $-3.28 | $-3.30 | $-3.89 | $-3.37 | $-0.32 | $-0.05 | $-4.20 | $-7.02 | $-2.40 | $-3.00 | $-0.66 |
| High Forecast | $-2.20 | $-1.70 | $-1.41 | $-1.49 | $-1.29 | $-2.80 | $-2.90 | $-3.03 | $-3.35 | $-3.85 | $-3.67 | $-3.78 | $-2.63 | $-3.37 | $-3.12 | $-2.63 | $-1.64 | $4.30 | $-2.60 | $-3.28 | $-3.30 | $-3.89 | $-3.37 | $-0.26 | $-0.04 | $-3.36 | $-5.62 | $-1.92 | $-2.40 | $-0.53 |
| Low Forecast | $-2.20 | $-1.70 | $-1.41 | $-1.49 | $-1.54 | $-2.80 | $-2.90 | $-3.03 | $-3.35 | $-3.85 | $-3.67 | $-3.78 | $-2.63 | $-3.37 | $-3.12 | $-2.63 | $-1.64 | $4.30 | $-2.60 | $-3.28 | $-3.30 | $-3.89 | $-3.37 | $-0.38 | $-0.06 | $-5.04 | $-8.42 | $-2.88 | $-3.60 | $-0.79 |
| Surprise % | - | - | - | - | 1.17% | - | 0.75% | -0.03% | 0.04% | 0.03% | -0.04% | 0.01% | 0.04% | 0.02% | 0.09% | 0.04% | 0.01% | -0.04% | 0.02% | 0.08% | 0.01% | -0.01% | 0.07% | 0.50% | 0.40% | - | - | - | - | - |
According to 1 Wall Street analysts, MEI Pharma's projected average Quarter EPS for Mar 23 is $-2.90, with a low estimate of $-2.90 and a high estimate of $-2.90. This represents a -3725.00% decrease compared to MEIP previous annual EPS of $0.08 (Dec 22).
MEI Pharma Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| KZR | Kezar Life Sciences | $0.79 | $17.50 | 2115.19% | Buy |
| VINC | Vincerx Pharma | $0.38 | $3.00 | 689.47% | Buy |
| SPRO | Spero Therapeutics | $1.28 | $10.00 | 681.25% | Buy |
| ATXI | Avenue Therapeutics | $2.00 | $12.00 | 500.00% | Buy |
| MEIP | MEI Pharma | $2.74 | $15.00 | 447.45% | Buy |
| CTMX | CytomX Therapeutics | $1.16 | $5.77 | 397.41% | Buy |
| INZY | Inozyme Pharma | $5.28 | $14.67 | 177.84% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.93 | $38.80 | 159.88% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.70 | $7.00 | 159.26% | Buy |
| TIL | Instil Bio | $34.90 | $78.25 | 124.21% | Hold |
| ASMB | Assembly Biosciences | $16.59 | $35.50 | 113.98% | Buy |
| ACHL | Achilles Therapeutics | $0.99 | $2.00 | 102.02% | Buy |
| TERN | Terns Pharmaceuticals | $7.24 | $14.25 | 96.82% | Buy |
| OCUL | Ocular Therapeutix | $11.37 | $17.50 | 53.91% | Buy |
| ZURA | Zura Bio | $4.83 | $5.00 | 3.52% | Buy |
| HOOK | HOOKIPA Pharma | $3.99 | $3.00 | -24.81% | Buy |
MEIP Forecast FAQ
Is MEI Pharma a good buy?
No, according to 3 Wall Street analysts, MEI Pharma (MEIP) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 0 'Buy' recommendations, accounting for 0% of MEIP's total ratings.
What are MEI Pharma's analysts' financial forecasts?
MEI Pharma's analysts financial forecasts for the fiscal year (Jun 2023) are as follows: average revenue is $9.8M (high $9.8M, low $9.8M), average EBITDA is $-20.997M (high $-17.255M, low $-24.739M), average net income is $-59.859M (high $-56.075M, low $-63.644M), average SG&A $6.51M (high $6.51M, low $6.51M), and average EPS is $-12.08 (high $-12.08, low $-12.08). MEIP's analysts financial forecasts for the fiscal year (Jun 2024) are as follows: average revenue is $187.5K (high $187.75K, low $187.25K), average EBITDA is $-11.015M (high $-8.826M, low $-13.205M), average net income is $-29.841M (high $-26.791M, low $-32.891M), average SG&A $124.5K (high $124.67K, low $124.34K), and average EPS is $-4.307 (high $-4.181, low $-4.433).
Did the MEIP's actual financial results beat the analysts' financial forecasts?
Based on MEI Pharma's last annual report (Jun 2022), the company's revenue was $40.7M, beating the average analysts forecast of $24.04M by 69.28%. Apple's EBITDA was $-95.91M, beating the average prediction of $-21.874M by 338.46%. The company's net income was $-54.738M, missing the average estimation of $-80.962M by -32.39%. Apple's SG&A was $30.54M, beating the average forecast of $15.96M by 91.31%. Lastly, the company's EPS was $-0.44, missing the average prediction of $-13.928 by -96.84%. In terms of the last quarterly report (Mar 2023), MEI Pharma's revenue was $5.89M, beating the average analysts' forecast of $346.75K by 1599.78%. The company's EBITDA was $-16.294M, beating the average prediction of $-11.708M by 39.17%. MEI Pharma's net income was $-14.485M, beating the average estimation of $-11.829M by 22.45%. The company's SG&A was $7.18M, beating the average forecast of $230.25K by 3018.77%. Lastly, the company's EPS was $-2.17, missing the average prediction of $-2.9 by -25.17%